share_log

Johnson & Johnson | 10-Q: Q3 2024 Earnings Report

Johnson & Johnson | 10-Q: Q3 2024 Earnings Report

强生 | 10-Q：2024财年三季报
美股SEC公告 ·  2024/10/24 04:05

Moomoo AI 已提取核心信息

Johnson & Johnson reported Q3 2024 revenue of $22.5 billion, up 5.2% year-over-year, with operational growth of 6.3% partially offset by a 1.1% negative currency impact. Innovative Medicine sales rose 4.9% to $14.6 billion, while MedTech revenue increased 5.8% to $7.9 billion. The quarter included a $1.25 billion charge for acquiring NM26 bispecific antibody rights.Net earnings declined to $2.7 billion from $4.3 billion in Q3 2023, primarily due to $2.0 billion in talc-related charges. The company recorded strong performance in key products, with DARZALEX sales up 20.7% to $3.0 billion and TREMFYA growing 13.0% to $1.0 billion. The MedTech segment was boosted by the Shockwave acquisition and double-digit growth in Electrophysiology.Looking ahead, J&J maintained its operational sales growth outlook and continues to pursue resolution of talc claims through multiple pathways. The company's financial position remains strong with $20.0 billion in cash and cash equivalents. The Board declared a quarterly dividend of $1.24 per share, demonstrating continued commitment to shareholder returns despite ongoing litigation challenges.
Johnson & Johnson reported Q3 2024 revenue of $22.5 billion, up 5.2% year-over-year, with operational growth of 6.3% partially offset by a 1.1% negative currency impact. Innovative Medicine sales rose 4.9% to $14.6 billion, while MedTech revenue increased 5.8% to $7.9 billion. The quarter included a $1.25 billion charge for acquiring NM26 bispecific antibody rights.Net earnings declined to $2.7 billion from $4.3 billion in Q3 2023, primarily due to $2.0 billion in talc-related charges. The company recorded strong performance in key products, with DARZALEX sales up 20.7% to $3.0 billion and TREMFYA growing 13.0% to $1.0 billion. The MedTech segment was boosted by the Shockwave acquisition and double-digit growth in Electrophysiology.Looking ahead, J&J maintained its operational sales growth outlook and continues to pursue resolution of talc claims through multiple pathways. The company's financial position remains strong with $20.0 billion in cash and cash equivalents. The Board declared a quarterly dividend of $1.24 per share, demonstrating continued commitment to shareholder returns despite ongoing litigation challenges.
强生在2024年第三季度报告的营业收入为225亿，同比增长5.2%，运营增长为6.3%，部分受到1.1%的负货币影响影响。创新医学销售增长4.9%，达到146亿，而医疗技术营收增长5.8%，达到79亿。本季度包括收购NM26双特异性抗体权利的125亿费用。净收益从2023年第三季度的43亿下降至27亿，主要由于与滑石粉相关的20亿费用。公司主要产品表现强劲，DARZALEX销售增长20.7%，达到30亿，TREMFYA增长13.0%，达到10亿。医疗技术部门受益于Shockwave收购和电生理领域的两位数增长。展望未来，强生维持其运营销售增长前景，并继续通过多种途径追求对滑石粉索赔的解决。公司的财务状况依然强劲，现金及现金等价物为200亿。董事会宣布每股1.24美元的季度股息，尽管面临持续的诉讼挑战，仍表现出对股东回报的持续承诺。
强生在2024年第三季度报告的营业收入为225亿，同比增长5.2%，运营增长为6.3%，部分受到1.1%的负货币影响影响。创新医学销售增长4.9%，达到146亿，而医疗技术营收增长5.8%，达到79亿。本季度包括收购NM26双特异性抗体权利的125亿费用。净收益从2023年第三季度的43亿下降至27亿，主要由于与滑石粉相关的20亿费用。公司主要产品表现强劲，DARZALEX销售增长20.7%，达到30亿，TREMFYA增长13.0%，达到10亿。医疗技术部门受益于Shockwave收购和电生理领域的两位数增长。展望未来，强生维持其运营销售增长前景，并继续通过多种途径追求对滑石粉索赔的解决。公司的财务状况依然强劲，现金及现金等价物为200亿。董事会宣布每股1.24美元的季度股息，尽管面临持续的诉讼挑战，仍表现出对股东回报的持续承诺。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间